文献速递胸部肿瘤头颈与中枢神经肿瘤

接受劳拉替尼治疗其他靶向治疗进展后患者发生神经认知不良事件的相关因素

Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
PubMed 文献 · J Thorac Oncol · 2022-09-29

研究回顾了麻省总医院(MGH,n=124)和1/2期B7461001研究(n=248)中接受劳拉替尼治疗的患者记录,分析合并症、基线用药与神经认知不良事件(NAE)的关联。多数患者发生NAE(MGH 60%,B7461001 49%),认知效应、情绪效应等与脑转移、脑放疗、精神疾病及神经药物使用相关。

要点

  • 劳拉替尼相关神经认知不良事件常见,MGH队列60%、B7461001队列49%发生NAE。
  • 脑转移、脑放疗、精神疾病、精神药物、抗癫痫药、兴奋剂与认知效应相关。
  • 情绪效应与精神疾病、兴奋剂、脑手术、苯二氮䓬类、镇静剂相关,精神病性效应少见。

核心结论

  • 劳拉替尼的神经认知效应常见,其相关NAE可能受多种因素影响,包括脑转移、脑放疗、精神疾病和使用亲神经药物。

研究设计与样本

  • 回顾性分析麻省总医院(MGH)前瞻性研究患者记录(n=124)和1/2期B7461001研究(NCT01970865)患者记录(n=248)。

主要发现

  • MGH队列60%、B7461001队列49%的患者发生NAE。
  • 认知效应在MGH队列为40%、B7461001队列为29%;情绪效应分别为36%和23%;精神病性效应分别为3%和9%;言语效应分别为23%和11%。
  • B7461001队列中,脑转移(p=0.008)、脑放疗(p=0.033)、精神疾病(p=0.008)、精神药物(p<0.001)、抗癫痫药(p<0.001)和兴奋剂(p=0.026)与发生认知效应相关。
  • MGH队列中,精神疾病(p=0.02)和兴奋剂(p=0.01)与发生情绪效应相关;B7461001队列中,脑手术(p=0.020)、精神药物(p<0.001)、苯二氮䓬类(p=0.002)和镇静剂(p=0.034)与发生情绪效应相关。
  • 精神病性效应在MGH队列与脑手术相关(p=0.001),在B7461001队列与年龄相关(p=0.014);B7461001队列中脑放疗(p=0.012)和抗癫痫药(p<0.001)与言语效应相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The safety profile of lorlatinib includes neurocognitive adverse events (NAEs). Baseline factors associated with developing NAEs remain poorly characterized. METHODS: Records from patients who received lorlatinib through prospective studies at Massachusetts General Hospital (MGH, n = 124) or the phase 1/2 B7461001 (NCT01970865; n = 248) study were reviewed to identify potential associations between comorbidities, baseline medications, and NAEs. RESULTS: Most patients experienced a NAE (MGH: 60%, B7461001: 49%). Cognitive effects occurred in 40% and 29% of patients in the MGH and B7461001 cohorts, respectively. Brain metastases (p = 0.008), brain radiation (p = 0.033), psychiatric illness (p = 0.008), psychiatric medications (p < 0.001), antiepileptics (p < 0.001), and stimulants (p = 0.026) were associated with developing cognitive effects in B7461001. Mood effects occurred in 36% and 23% of patients in the MGH and B7461001 cohorts, respectively. In the MGH cohort, psychiatric illness (p = 0.02) and stimulants (p = 0.01) were associated with developing mood effects whereas brain surgery (p = 0.020), psychiatric medications (p < 0.001), benzodiazepines (p = 0.002), and sedatives (p = 0.034) were associated with developing mood effects in B7461001. Psychotic effects were infrequent (MGH: 3%, B7461001: 9%) and were associated with brain surgery in the MGH cohort (p = 0.001) and age in B7461001 (p = 0.014). Speech effects were observed in 23% and 11% of patients in the MGH and B7461001 cohorts, respectively. Brain radiation (p = 0.012) and antiepileptics (p < 0.001) were associated with speech effects in B7461001. Dose reductions were implemented for 52% and 18% of patients with NAEs in MGH and B7461001 cohorts, respectively, with mitigating effect. CONCLUSIONS: Neurocognitive effects from lorlatinib are common. Lorlatinib-related NAEs may be influenced by multiple factors, including brain metastases, brain radiation, psychiatric illness, and use of neurotropic medications.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dagogo-Jack I, Abbattista A, Murphy JF, et al. Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies. J Thorac Oncol. 2022. PMID: 36184067. doi:10.1016/j.jtho.2022.09.219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。